Want to see SINT full AI Analyst Report?
Top Page
Sintx Technologies
(NASDAQ:SINT)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-59.89% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance—persistent losses and significant negative operating/free cash flow that increase liquidity and financing risk. Technicals also lean weak with the stock below key longer-term moving averages and a negative MACD. Offsetting factors are mainly from the earnings call: strong year-over-year revenue growth, improved gross margin, and near-term revenue guidance, but these are tempered by going-concern and execution/recognition uncertainty.
Positive Factors
Revenue and Margin Expansion
Higher product revenue and materially improved gross margin indicate stronger commercial traction and better pricing or mix. If sustained beyond the small current revenue base, these trends could improve operating leverage and support a more scalable business model.
Negative Factors
Persistent Cash Burn and Liquidity Risk
Sustained negative operating and free cash flow means the company cannot currently fund operations internally. Continued cash consumption raises dependence on external financing and creates a durable risk to commercialization, investment capacity, and financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Expansion
Higher product revenue and materially improved gross margin indicate stronger commercial traction and better pricing or mix. If sustained beyond the small current revenue base, these trends could improve operating leverage and support a more scalable business model.
Read all positive factors
Sintx Technologies (SINT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.60M
Dividend YieldN/A
Average Volume (3M)148.79K
Price to Earnings (P/E)―
Beta (1Y)2.60
Revenue Growth-28.53%
EPS Growth47.55%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,664,534
10 Day Avg. Volume107,243
30 Day Avg. Volume148,787
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.66
Price to Sales (P/S)10.52
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside113.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sintx Technologies Business Overview & Revenue Model
Company Description
Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, p...
How the Company Makes Money
null...
Sintx Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38M | 1.02M | 1.25M | 2.63M | 601.00K | 606.00K |
| Gross Profit | -64.00K | -201.00K | 435.00K | 1.84M | 336.00K | 157.00K |
| EBITDA | -10.71M | -9.65M | -9.61M | -6.60M | -11.06M | -8.63M |
| Net Income | -18.00M | -17.08M | -11.02M | -8.26M | -12.04M | -9.31M |
Balance Sheet | ||||||
| Total Assets | 10.43M | 9.51M | 9.41M | 15.37M | 15.77M | 21.84M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 4.14M | 3.60M | 3.34M | 6.25M | 14.27M |
| Total Debt | 3.05M | 3.25M | 4.03M | 4.76M | 3.63M | 2.91M |
| Total Liabilities | 5.60M | 6.58M | 5.52M | 6.59M | 10.07M | 4.64M |
| Stockholders Equity | 4.83M | 2.93M | 3.89M | 8.77M | 5.70M | 17.20M |
Cash Flow | ||||||
| Free Cash Flow | -10.34M | -8.76M | -9.33M | -14.64M | -11.67M | -13.87M |
| Operating Cash Flow | -10.12M | -8.57M | -8.64M | -14.12M | -10.26M | -10.13M |
| Investing Cash Flow | 533.00K | 913.00K | -194.00K | -501.00K | -1.10M | -1.66M |
| Financing Cash Flow | 8.86M | 8.20M | 9.09M | 11.71M | 3.34M | 705.00K |
Sintx Technologies Technical Analysis
Negative
3.74
Price Trends
1.75
Negative
2.08
Negative
2.69
Negative
Market Momentum
-0.04
Positive
41.37
Neutral
23.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SINT, the sentiment is Negative. The current price of 3.74 is above the 20-day moving average (MA) of 1.62, above the 50-day MA of 1.75, and above the 200-day MA of 2.69, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 41.37 is Neutral, neither overbought nor oversold. The STOCH value of 23.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SINT.
Sintx Technologies Risk Analysis
Sintx Technologies disclosed 38 risk factors in its most recent earnings report. Sintx Technologies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sintx Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $19.21B | 23.96 | 6.36% | 1.05% | 8.62% | 0.09% | |
72 Outperform | $130.41B | 33.68 | 16.36% | 1.05% | 8.48% | 27.36% | |
55 Neutral | $120.49B | 24.61 | 9.85% | 3.43% | 8.43% | 3.17% | |
55 Neutral | $426.88M | -6.52 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.34B | -179.93 | -0.69% | ― | 1.60% | 98.56% | |
44 Neutral | $10.60M | -0.28 | -592.55% | ― | -28.53% | 47.55% |
* Healthcare Sector Average
SINT
Sintx Technologies
1.51
-1.75
-53.68%
IART
Integra Lifesciences
16.59
2.91
21.27%
MDT
Medtronic
92.30
4.07
4.61%
OFIX
Orthofix Medical
10.01
-4.54
-31.20%
SYK
Stryker
327.70
-53.25
-13.98%
ZBH
Zimmer Biomet Holdings
98.97
-4.36
-4.22%
Sintx Technologies Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
SINTX Regains Nasdaq Compliance, Supporting Growth Initiatives
Positive
Aug 13, 2026
On August 12, 2026, SINTX Technologies received notice from Nasdaq’s Listing Qualifications Staff that it had regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2.5 million under Lis...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Sintx Technologies Advances Commercialization and Strengthens Financial Position
Positive
Aug 11, 2026
During the first half of 2026, SINTX advanced commercialization of its SiNAPTIC Foot Ankle Implant and Osteotomy Wedge Systems following FDA clearance in October 2025, building a U.S. network of twelve independent orthopedic distributors. Managem...
Business Operations and StrategyRegulatory Filings and Compliance
Sintx Technologies Restructures Warrants and Equity Positions
Neutral
Jul 2, 2026
On June 29, 2026, Sintx Technologies and MedTech Ceramics, LP executed a letter agreement to resolve the disposition of 507,254 common shares held in abeyance from a September 2025 warrant inducement and to overhaul the holder’s warrant posi...
Business Operations and StrategyPrivate Placements and Financing
Sintx Technologies Announces New Private Placement Financing
Positive
Jun 3, 2026
On June 2, 2026, SINTX Technologies entered into securities purchase agreements with institutional and accredited investors for a private placement of 1,882,845 units, each comprising one common share plus Class A and Class B warrants, raising gro...
Delistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Sintx Technologies Faces Nasdaq Noncompliance, Plans Remediation
Negative
May 27, 2026
On May 22, 2026, SINTX Technologies received a notice from Nasdaq that it was no longer in compliance with the exchange’s requirement to maintain at least $2.5 million in stockholders’ equity, after reporting approximately $904,000 in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.